Ryan Iarrobino - Scholar Rock Senior Operations
| SRRK Stock | USD 39.90 1.75 4.59% |
Executive
Ryan Iarrobino is Senior Operations of Scholar Rock Holding
| Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 857 259 3860 |
| Web | https://scholarrock.com |
Scholar Rock Management Efficiency
The company has return on total asset (ROA) of (0.671) % which means that it has lost $0.671 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8307) %, meaning that it created substantial loss on money invested by shareholders. Scholar Rock's management efficiency ratios could be used to measure how well Scholar Rock manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.56. The value of Return On Capital Employed is expected to slide to -0.65. At this time, Scholar Rock's Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 53.2 M this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 252.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| JD Esq | Ideaya Biosciences | 52 | |
| Tim Randall | MeiraGTx Holdings PLC | N/A | |
| John III | Avidity Biosciences | 66 | |
| Monique Silva | AnaptysBio | N/A | |
| Kathleen Borthwick | Passage Bio | 47 | |
| Douglas Snyder | Ideaya Biosciences | 60 | |
| Jim Watters | Relay Therapeutics | N/A | |
| Alexander Constan | Ikena Oncology | N/A | |
| Rose Weldon | Cullinan Oncology LLC | N/A | |
| John Northcott | Arvinas | 46 | |
| Bob Lally | Ikena Oncology | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Samantha Vuksanic | Ikena Oncology | N/A | |
| Marvin Peterson | IGM Biosciences | N/A | |
| Moriarty ESQ | Avidity Biosciences | 56 | |
| Lily Cheung | Pliant Therapeutics | 51 | |
| Faraz Siddiqui | IGM Biosciences | N/A | |
| Eric Loumeau | AnaptysBio | 61 | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Jeff Boyle | Arvinas | N/A | |
| Gregory Fuest | Passage Bio | N/A | |
Management Performance
| Return On Equity | -1.83 | ||||
| Return On Asset | -0.67 |
Scholar Rock Holding Leadership Team
Elected by the shareholders, the Scholar Rock's board of directors comprises two types of representatives: Scholar Rock inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scholar. The board's role is to monitor Scholar Rock's management team and ensure that shareholders' interests are well served. Scholar Rock's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scholar Rock's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin CPA, Senior Finance | ||
| Junlin JD, General Secretary | ||
| Erin Moore, Senior Finance | ||
| Catherine Hu, IR Contact Officer | ||
| Caryn Parlavecchio, Chief Officer | ||
| Lisa Price, Senior Resources | ||
| MBA MD, Chief Officer | ||
| Mo Qatanani, Senior Research | ||
| Edward MBA, COO CFO | ||
| Rushmie Nofsinger, Vice Relations | ||
| Ryan Iarrobino, Senior Operations | ||
| MBA MBA, COO CFO | ||
| MPH MD, CEO President | ||
| Tracey MBA, Chief Officer |
Scholar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scholar Rock a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.83 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 3.5 B | ||||
| Shares Outstanding | 93.61 M | ||||
| Shares Owned By Insiders | 1.07 % | ||||
| Shares Owned By Institutions | 98.39 % | ||||
| Number Of Shares Shorted | 15.14 M | ||||
| Price To Book | 45.10 X | ||||
| Price To Sales | 13.14 X | ||||
| Gross Profit | (89.85 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Scholar Rock Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scholar Rock. If investors know Scholar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scholar Rock listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.36) | Quarterly Revenue Growth (1.00) | Return On Assets (0.67) | Return On Equity (1.83) |
The market value of Scholar Rock Holding is measured differently than its book value, which is the value of Scholar that is recorded on the company's balance sheet. Investors also form their own opinion of Scholar Rock's value that differs from its market value or its book value, called intrinsic value, which is Scholar Rock's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scholar Rock's market value can be influenced by many factors that don't directly affect Scholar Rock's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scholar Rock's value and its price as these two are different measures arrived at by different means. Investors typically determine if Scholar Rock is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scholar Rock's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.